Alpelisib

Brand names: Piqray · Active ingredient: Alpelisib

In short: PIQRAY is indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-authorized test following progression on or after

Forms & strengthsTablets: 50 mg, 150 mg, and 200 mg alpelisib 50 mg: Light pink, unscored, round and curved with beveled edges film-coated tablet, imprinted with “L7” on one side and “NVR” on the other side. …
LabelNovartis Pharmaceuticals Corporation
Label updatedNov 05, 2026

What is Alpelisib used for?

PIQRAY is indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-authorized test following progression on or after an endocrine-based regimen.

Alpelisib dosage

Select patients for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer with PIQRAY, based on the presence of one or more PIK3CA mutations in tumor tissue or plasma specimens . If no mutation is detected in a plasma specimen, test tumor tissue. Information on FDA-authorized tests for the detection of PIK3CA mutations in breast cancer is available at: http://www.fda.gov/CompanionDiagnostics.

The recommended dosage of PIQRAY is 300 mg orally once daily with food until disease progression or unacceptable toxicity occurs.

Patients should take their dose of PIQRAY at approximately the same time each day.

Swallow PIQRAY tablets whole (tablets should not be chewed, crushed or split prior to swallowing). No tablet should be ingested if it is broken, cracked, or otherwise not intact.

If a dose of PIQRAY is missed, it can be taken with food within 9 hours after the time it is usually taken. After more than 9 hours, skip the dose for that day. The next day, take PIQRAY at the usual time.

If the patient vomits after taking a dose, advise the patient not to take an additional dose on that day, and to resume the dosing schedule the next day at the usual time.

When given with PIQRAY, the recommended dose of fulvestrant is 500 mg administered on Days 1, 15, and 29, and once monthly thereafter. Refer to the Prescribing Information for fulvestrant.

The recommended dosage modifications for adverse reactions are listed in Table 1.

1Only one dose reduction is permitted for pancreatitis.

2If further dose reduction below 200 mg once daily is required, discontinue PIQRAY.

PIQRAY dose level | Dose and schedule | Number and strength of tablets

Starting dose | 300 mg once daily | Two 150 mg tablets

First-dose reduction | 250 mg once daily | One 200 mg tablet and one 50 mg tablet

Second-dose reduction | 200 mg once daily2 | One 200 mg tablet

Tables 2, 3, 4, and 5 summarize recommendations for dose interruption, reduction, or discontinuation of PIQRAY in the management of specific adverse reactions.

Cutaneous Adverse Reactions

If a severe cutaneous adverse reaction (SCAR) is confirmed, permanently discontinue PIQRAY. Do not reintroduce PIQRAY in patients who have experienced previous SCAR during PIQRAY treatment .

1Grading according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

2For all grades of rash, consider consultation with a dermatologist.

3Antihistamines administered prior to rash onset may decrease incidence and severity of rash based on the SOLAR-1 trial. …

How to take Alpelisib — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Severe Hypersensitivity

Inform patients of the signs and symptoms of hypersensitivity. Advise patients to contact their healthcare provider immediately for signs and symptoms of hypersensitivity .

Severe Cutaneous Adverse Reactions

Inform patients of the signs and symptoms of severe cutaneous adverse reactions (SCARs). Advise patients to contact their healthcare provider immediately for signs and symptoms of SCARs .

Hyperglycemia

Advise patients that PIQRAY may cause hyperglycemia and the need to monitor fasting blood glucose periodically during therapy. Advise patients to contact their healthcare provider immediately for signs and symptoms of hyperglycemia .

Pneumonitis

Inform patients that PIQRAY may cause pneumonitis and to immediately contact their healthcare provider if they experience respiratory problems .

Diarrhea or Colitis

Advise patients that PIQRAY may cause diarrhea, which may be severe, and to start antidiarrheal treatment, increase oral fluids, and notify their healthcare provider if diarrhea occurs while taking PIQRAY . …

Warnings & precautions

Do not take this medicine if: PIQRAY is contraindicated in patients with severe hypersensitivity to it or any of its components .

Severe hypersensitivity reactions, including anaphylaxis and anaphylactic shock, can occur in patients treated with PIQRAY. Severe hypersensitivity reactions were manifested by symptoms, including, but not limited to, dyspnea, flushing, rash, fever, or tachycardia.

The incidence of Grade 3 and 4 hypersensitivity reactions was 0.7% .

Angioedema has been reported in the postmarketing setting in patients treated with PIQRAY .

Advise patients of the signs and symptoms of severe hypersensitivity reactions. Permanently discontinue PIQRAY in the event of severe hypersensitivity.

Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), erythema multiforme (EM), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) can occur in patients treated with PIQRAY.

In the SOLAR-1 study, SJS and EM were reported in 0.4% and 1.1% of the patients, respectively . Drug reaction with eosinophilia and systemic symptoms (DRESS) was reported in patients treated with PIQRAY in the postmarketing setting .

If signs or symptoms of SCARs occur, interrupt PIQRAY until the etiology of the reaction has been determined. Consultation with a dermatologist is recommended.

If a SCAR is confirmed, permanently discontinue PIQRAY. Do not reintroduce PIQRAY in patients who have experienced previous severe cutaneous adverse reactions during PIQRAY treatment.

If a SCAR is not confirmed, PIQRAY may require dose modifications, topical corticosteroids, or oral antihistamine treatment as described in Table 2 .

Advise patients of the signs and symptoms of SCARs (e.g., a prodrome of fever, flu-like symptoms, mucosal lesions, progressive skin rash, or lymphadenopathy). …

Alpelisib side effects

The following adverse reactions are discussed in greater detail in other sections of the labeling:

Severe Hypersensitivity

Severe Cutaneous Adverse Reactions

Hyperglycemia

Pneumonitis

Diarrhea or Colitis

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of PIQRAY was evaluated in a randomized, double-blind, placebo-controlled trial (SOLAR-1) in 571 patients with HR-positive, HER2-negative, advanced or metastatic breast cancer enrolled into two cohorts, with or without a PIK3CA mutation .

Patients received either PIQRAY 300 mg plus fulvestrant (n = 284) or placebo plus fulvestrant (n = 287). Fulvestrant 500 mg was administered intramuscularly on Cycle 1, Day 1 and 15, and then at Day 1 of each 28-day cycle during treatment phase.

Two patients (0.7%) died while on treatment with PIQRAY plus fulvestrant due to causes other than the underlying malignancy. Causes of death included one cardio-respiratory arrest and one second primary malignancy. Neither was suspected to be related to study treatment.

Serious adverse reactions occurred in 35% of patients receiving PIQRAY plus fulvestrant. …

Drug interactions

Strong CYP3A Inducer

Avoid coadministration of strong CYP3A inducers with PIQRAY and consider an alternative concomitant drug with no or minimal potential to induce CYP3A.

Alpelisib is a CYP3A substrate . Coadministration with a strong CYP3A inducer decreases alpelisib concentration , which may reduce alpelisib effectiveness.

BCRP Inhibitors

Avoid coadministration of BCRP inhibitors with PIQRAY. If cannot avoid coadministration, monitor for increased adverse reactions.

Alpelisib is a BCRP substrate . Coadministration of PIQRAY with a BCRP inhibitor may increase alpelisib concentration , which may increase the risk of adverse reaction.

About this medicine

PIQRAY (alpelisib) is a kinase inhibitor. The chemical name of alpelisib is (2S)-N

1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide. Alpelisib is a white to almost white powder. The molecular formula for alpelisib is C19H22F3N5O2S and the relative molecular mass is 441.47 g/mol. The chemical structure of alpelisib is shown below:

PIQRAY film-coated tablets are supplied for oral administration with three strengths that contain 50 mg, 150 mg and 200 mg of alpelisib. The tablets also contain hypromellose, magnesium stearate, mannitol, microcrystalline cellulose, and sodium starch glycolate. The film-coating contains hypromellose, iron oxide black, iron oxide red, macrogol/polyethylene glycol (PEG) 4000, talc, and titanium dioxide.

How it works: Alpelisib is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3Kα. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID b20b4e18-7a4b-4500-a08f-06c6dab0ee5b. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate